Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 529-536

  Mohamed, Elnisr Rashed ^a   Naito, Masayasu ^a   Terasaki, Yasunobu ^a   Niu, Yamei ^a   Gohara, Shojiro ^a   Komatsu, Nobukazu ^a   Shichijo, Shigeki ^a   Itoh, Kyogo ^a   Noguchi, Masanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T cell; HLA; Peptide; Prostate cancer; SART3

Indexed keywords

HLA A11 ANTIGEN; HLA A24 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; TUMOR REJECTION ANTIGEN; TUMOR REJECTION ANTIGEN SART3 [109-118]; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INTERFERON PRODUCTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ACTINS; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DNA PRIMERS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 64549097297     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000178     Document Type: Article

References (40)

1. Shichijo S, Nakao M, Imai Y, et al: A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187: 277-288, 1998.
2. Yang D, Nakao M, Shichijo S, et al: Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056-4063, 1999.
3. Nakao M, Shichijo S, Imaizumi, et al: Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 164: 2565-2574, 2000.
4. Ito M, Shichijo S, Miyagi Y, et al: Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88: 633-639, 2000.
5. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
6. Nakatsura T, Senju S, Ito M, Nishimura Y and Itoh K: Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32: 826-836, 2002.
7. + cancer patients. Clin Cancer Res 10: 1112-1120, 2004.
8. Matsueda S, Takedatsu H, Yao A, et al: Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 11: 6933-6943, 2005.
9. Minami T, Matsueda S, Takedatsu H, et al: Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 56: 689-698, 2007.
10. Noguchi M, Kobayashi K, Suetsugu N, et al: Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57: 80-92, 2003.
11. Sato Y, Shomura H, Maeda Y, et al: Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802-808, 2003.
12. Noguchi M, Itoh K, Suekane S, et al: Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 95: 77-84, 2004.
13. Mine T, Sato Y, Noguchi M, et al: Humoral responses to peptides correlated with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10: 929-937, 2004.
14. Tatedatsu H, Yoshimoto K, Yakushiji K, et al: Expression of epithelial cancer-related antigens in hematologic malignancies applicable for peptide-based immunotherapy. J Immunother 27: 289-297, 2004.
15. Itoh K and Yamada A: Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci 97: 970-976, 2006.
16. Sette A and Sidney J: Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212, 1999.
17. Imanishi T, Akazawa T and Kimura A: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991. Tsuji K, Aizawa M and Sasazuki T (eds). Vol. 1, Oxford Scientific Publications, Oxford, pp1065-1220, 1992.
18. Murayama K, Kobayashi T, Imaizumi T, et al: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 23: 511-518, 2000.
19. Miyagi Y, Imai M, Sasatomi T, et al: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 7: 3950-3962, 2001.
20. Suzuki N, Maeda Y, Tanaka S, et al: Detection of peptide-specific cytotoxic T lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 98: 45-50, 2002.
21. Sasatomi T, Suefuji Y, Matsunaga K, et al: Expression of tumor rejection antigens in colorectal carcinomas. Cancer 94: 1636-1641, 2002.
22. Kawagoe N, Shintaku I, Yutani S, et al: Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 164: 2090-2095, 2000.
23. Niiya F, Nishizaka S, Matsunaga K, et al: Expression of SART3 tumor-rejection antigen in gastric cancers. Jpn J Cancer Res 91: 337-342, 2000.
24. Tanaka S, Tsuda N, Kawano K, et al: Expression of tumor-rejection antigens in gynecologic cancers. Jpn J Cancer Res 91: 1177-1184, 2000.
25. Tsuda N, Murayama K, Ishida H, et al: Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 19: 346-351, 2001.
26. Tanaka M, Komatsu N, Yanagimoto Y, et al: Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes. Kurume Med J 53: 63-70, 2006.
27. Ohkouchi S, Yamada A, Imai N, et al: Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 59: 259-272, 2002.
28. Hoa BK, Hang NTL, Kashiwase K, et al: HLA-A, -B, -C, -DRB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue Antigens 71: 127-134, 2007.
29. Anderson KS, Alexander J, Wei M and Cresswell P: Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol 151: 3407-3419, 1993.
30. Takao Y, Yamada A, Yutani S, Sata M and Itoh K: Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction. Microbiol Immunol 48: 507-511, 2004.
31. Maier R, Falk K, Rötzschke O, et al: Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 40: 306-308, 1994.
32. Takiguchi M, Matsuda T and Tomiyama H: Polarity of the P1 anchor residue determines peptide binding specificity between HLA-A*3101 and HLA-A*3303. Tissue Antigens 56: 501-506, 2000.
33. Wang RF, Johnston SL, Southwood S, Sette A and Rosenberg SA: Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 160: 890-897, 1998.
34. Komatsu N, Shichijo S, Nakagawa M and Itoh K: New multi-plexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64: 535-545, 2004.
35. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219-228, 2002.
36. Takamiya Y, Schönbach C, Nokihara K, et al: HLA-B*3501- peptide interactions: role binding to HLA-B*3501 molecules. Int Immunol 6: 255-261, 1994.
37. Liang B, Zhu L, Liang Z, et al: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol 3: 453-458, 2006.
38. Krausa P, Brywka M III, Savage D, et al: Genetic polymorphism within HLA A*02: significant allelic variation revealed in different populations. Tissue Antigens 45: 223-231, 1995.
39. Rammensee HG, Friege T and Stevanovics S: MHC ligands and peptides motifs. Immunogenetics 41: 178-228, 1995.
40. Sidney J, Grey HM, Southwood S, et al: Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 45: 79-93, 1996.